Serascience, a joint venture between Abingdon Health and the University of Birmingham, has introduced a proprietary point-of-care diagnostic device for multiple myeloma.
Designed to aid in the diagnosis of myeloma and monitor relapse and monoclonal gammopathies of undetermined significance (MGUS ) progression, the device measures two markers of myeloma including kappa and lambda free light chains.
The device then calculates the ratio of the two markers in urine, blood or serum and provides results within ten minutes.
Delays in diagnosis can result in anaemia, infection and severe damage to the kidneys and skeleton, according to the company.
University of Birmingham clinical immunology service director Mark Drayson said early diagnosis is critical for patients with myeloma.
"The faster the treatment process can begin, the greater the chance of survival," Drayson added.
"Currently 50% of patients with myeloma require three or more visits to their GP before they are referred to hospital.
"The launch of a point-of-care test is an important step in improving patient outcomes and we welcome this development."
